Not recruiting

Study of dupilumab added to inhaled corticosteroids and long-acting beta-agonists compared to high-dose inhaled therapy in adolescents and adults with uncontrolled asthma

Fast replyRegistered drug

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on uncontrolled asthma in adolescents and adults who are currently using medium-dose inhaled medications. The research compares two different treatment approaches: adding dupilumab to the current treatment versus increasing the dose of existing medication. The current treatment includes Advair HFA, which contains two active substances: fluticasone propionate and salmeterol.

The main purpose is to determine if adding dupilumab to the current medium-dose treatment is more effective at reducing severe asthma attacks compared to increasing the dose of Advair HFA. Some participants will receive dupilumab injections under the skin, while others will receive placebo injections. All participants will continue using their asthma inhalers throughout the study.

The study treatment will continue for approximately one year. During this time, participants will need to use their prescribed medications regularly and attend clinic visits for monitoring their asthma condition. The study will track various aspects of breathing function and how well asthma symptoms are controlled. The medications used in this study are designed to help control inflammation in the airways and make breathing easier for people with asthma.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Initial medication period
You will continue using your current medium dose ICS/LABA inhaler (containing fluticasone propionate and salmeterol) for at least 3 months with a stable dose
Your current inhaler must be used consistently, at least 80% of prescribed days
Step 2
Treatment assignment
You will be assigned to one of two treatment groups:
Group 1: Dupixent (dupilumab) 300 mg injection under the skin plus medium dose inhaler
Group 2: High-dose inhaler (Advair HFA 230mcg/21mcg) plus placebo injection
Step 3
Regular assessments
Your lung function will be measured through breathing tests that check:
- How much air you can breathe out in one second (FEV1)
- How much air you can exhale in total (FVC)
- How fast you can blow air out (peak flow)
You will complete questionnaires about your asthma control (ACQ-5)
Step 4
Monitoring period
The study will continue until December 2026
Any breathing problems or asthma attacks will be recorded
Any side effects from the medications will be documented
Your use of additional asthma medications will be tracked

Who can join the trial?

8 criteria

Must be between 12 and 80 years old when signing the consent form and have been diagnosed with asthma for at least 12 months
Must be currently using medium-dose inhaled corticosteroids (ICS) with long-acting beta-agonists (LABA) for at least 3 months, with a stable dose for at least 1 month before the first visit
Can be using up to 3 different asthma control medications
Must show improvement in lung function tests (FEV1 - the amount of air you can forcefully exhale in one second) after using an inhaler with albuterol/salbutamol
Must demonstrate regular use of prescribed asthma medications on at least 80% of days during the initial study period
Must have an ACQ-5 score of 1.5 or higher at the first screening visit (ACQ-5 is a questionnaire that measures how well your asthma is controlled)
Must have experienced at least 1 severe asthma flare-up in the past year, but not in the 30 days before the first visit
Must have a blood test showing 300 or more eosinophil cells (a type of white blood cell) per microliter of blood at the first visit

Who cannot join the trial?

15 criteria

Patients who have participated in any clinical trial within the past 30 days
Individuals with severe lung diseases other than asthma
Current smokers or those who quit smoking less than 6 months ago
People with a history of chronic obstructive pulmonary disease (COPD) - a long-term lung condition that causes breathing difficulties
Those with known allergies or sensitivity to dupilumab or similar medications
Patients with active parasitic infections
People with significant heart, liver, or kidney problems
Those with uncontrolled high blood pressure
Pregnant or breastfeeding women
Patients using medications that could interfere with the study drug
People with a history of cancer in the past 5 years (except for successfully treated skin cancer)
Individuals with serious infections requiring hospitalization in the past 4 weeks
Those with poorly controlled diabetes
Patients who have received any biological therapy for asthma in the past 4 months
People with a history of alcohol or drug abuse in the past year

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Diamond Clinic Sp. z o.o.
Responsive
Cracow, Poland
Not recruiting
Herlev Hospital
Verified
Herlev, Denmark
Hvidovre Hospital
Verified
Hvidovre, Denmark

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Dupilumab
is a medication used to treat severe asthma. It works by blocking certain proteins in the body that cause inflammation in the airways. This medication is given as an injection and helps reduce asthma attacks in people whose asthma is not well controlled with other medications.
Inhaled Corticosteroids (ICS)
are anti-inflammatory medications that help reduce swelling and mucus production in the airways. They are taken through an inhaler and help prevent asthma symptoms.
Long-Acting Beta Agonists (LABA)
are medications that help relax and open the airways. They are typically used together with inhaled corticosteroids in a combination inhaler. These medications provide long-lasting relief of asthma symptoms by keeping the airways open for an extended period.

What is already known about the treatment

Dupilumab - A biologic medication administered through subcutaneous injection that works by blocking specific proteins (interleukin-4 and interleukin-13) involved in allergic inflammation. This monoclonal antibody is primarily used for treating moderate to severe asthma in patients whose condition remains uncontrolled with standard inhaled corticosteroids and long-acting beta-agonists (ICS/LABA). The medication belongs to the class of biological disease-modifying drugs and functions by reducing inflammation in the airways, helping to prevent severe asthma attacks and improve lung function. Dupilumab represents a targeted approach in asthma treatment, particularly beneficial for patients who don't achieve adequate control with conventional therapy.

Investigated diseases

Asthma – A chronic respiratory condition that affects the airways in the lungs, causing them to become inflamed and narrowed. The airways become sensitive to various triggers such as allergens, irritants, or physical activity, leading to recurring episodes of breathing difficulties. During an asthma episode, the muscles around the airways tighten, the lining of the airways becomes swollen, and more mucus is produced than usual. These changes cause symptoms like wheezing, coughing, chest tightness, and shortness of breath. The severity of symptoms can vary from mild to severe, and they may come and go over time.